SemiVoice

seekingalpha

02/17/2025, 06:27 AM UTC

辉瑞：丹那格利普可能在几年内扭转局面，但现阶段建议卖出Pfizer: Danuglipron Could Tip The Scale In A Few Years, But For Now, Sell

1、我预计辉瑞未来18-24个月将面临来自医疗保险D部分改革和专利到期的持续逆风，建议卖出。2、如果2025年后期试验成功，丹那格利普可能成为扭转局面的催化剂。3、短期内，6.6%的股息率和低估值比率可能吸引价值投资者。

1. I rate Pfizer a sell for the next 18-24 months due to continued headwinds from Medicare Part D redesign and patent expirations. 2. Danuglipron could be a catalyst for a turnaround if late-stage trials succeed in 2025. 3. Short-term, the 6.6% yield and low valuation ratios may attract value investors.

---

本文由大语言模型（LLM）生成，旨在为读者提供半导体新闻内容的知识扩展（Beta）。